TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06465953
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
Study: NCT06333769
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab：200mg，d1，q3w，2 cycles.
Study: NCT06333769
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin：130mg/m2, d1, q3w, 2 cycles
Study: NCT04741542
Drug: SP-420
Normalized name: SP-420
DrugBank: SP-420 (DB16069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
Study: NCT05047783
Drug: Masitinib Mesylate
Normalized name: Axitinib
DrugBank: Masitinib (DB11526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3CL-protease inhibitor
Study: NCT05847517
Drug: Metoprolol Injection
Normalized name: metoprolol Injection
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted.
Study: NCT06478719
Drug: FB-1603
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FB-1603 (165 mg/cap) oral capsule
Study: NCT04890041
Drug: TPO-RA
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10\^9/L and 150×10\^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10\^9/L, the treatment was stopped. If the platelet count is more than 400×10\^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
Study: NCT05737628
Drug: BYON4228 + Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks until disease progression or unacceptable toxicity. Different doses.~Rituximab IV infusion (375 mg/m2) starting from the second treatment cycle onwards. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles.
Study: NCT06280092
Drug: AMSCs
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
Study: NCT05789602
Drug: BPI-460372
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BPI-460372 until disease progression
Study: NCT05676931
Drug: Domvanalimab
Normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05676931
Drug: Quemliclustat
Normalized name: Quemliclustat
DrugBank: Quemliclustat (DB19160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05676931
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05676931
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05676931
Drug: Platinum-Based Doublet
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05273320
Drug: Nabilone
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabilone capsules at a maximum dose of 1 mg twice a day
Study: NCT05424549
Drug: Reproxalap Ophthalmic Solution (0.25%)
Normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
Study: NCT05424549
Drug: Vehicle Ophthalmic Solution
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution dosed six times over two consecutive days
Study: NCT04985396
Drug: Platelet Rich Plasma (PRP) group
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
Study: NCT06064500
Drug: Tarlatamab
Normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.
Study: NCT04572763
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04572763
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet taken orally
Study: NCT05592418
Drug: Rintatolimod
Normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 to 400 mg twice weekly
Study: NCT05089448
Drug: Alisartan, Amlodipine besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs will be taken once daily at 6:00-10:00.
Study: NCT05089448
Drug: Alisartan, Amlodipine besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs will be taken once daily at 20:00-24:00.
Study: NCT04509102
Drug: Adderall-XR
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
Study: NCT06010329
Drug: Sutetinib Maleate Capsule
Normalized name: chlorpheniramine maleate Oral Capsule
DrugBank: Sutetinib (DB18841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04855747
Drug: REL-1017
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 tablet
Study: NCT05477407
Drug: Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
Study: NCT04931095
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis will be orally ingested via a brownie
Study: NCT04931095
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol will be orally ingested via a flavored drink
Study: NCT06540326
Drug: irinotecan liposome (II)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
Study: NCT06540326
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
Study: NCT06540326
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
Study: NCT05549258
Drug: Inebilizumab
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inebilizumab administered intravenously (IV) over a total of 28 weeks.
Study: NCT05400369
Drug: Sitafloxacin
Normalized name: sitafloxacin
DrugBank: Sitafloxacin (DB13261)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral administration, 50 mg tablets
Study: NCT05400369
Drug: Moxifloxacin Hydrochloride
Normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration, 400 mg tablets
Study: NCT05917158
Drug: RC48-ADC and JS001
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in group will receive 6 x 3 week cycles of RC48-ADC (Disitamab Vedotin) 2mg/kg in combination with JS001 (Toripalimab) 3mg/kg intravenously, followed by toripalimab (3 mg/kg) every 3 weeks for up to 1 year.
Study: NCT06279234
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral suspension
Study: NCT06279234
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06279234
Drug: PF-06954522
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06408298
Drug: Hydroxychloroquine Sulfate 400Mg Tab
Normalized name: HYDROXYCHLOROQUINE SULFATE 400MG TAB
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydroxychloroquine sulfate tablet
Study: NCT06029270
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06029270
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06029270
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05061368
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.
Study: NCT04995419
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Infusion
Study: NCT06450925
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.
Study: NCT05260684
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 450 mg QD
Study: NCT05260684
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg BID
Study: NCT05260684
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 960 mg BID for 28 days/cycle
Study: NCT05260684
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg QD for 21 days/cycle
Study: NCT05260684
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg BID
Study: NCT05260684
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg QD
Study: NCT04386070
Drug: RESP301
Normalized name: RESP301
DrugBank: RESP301 (DB16497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
Study: NCT06411639
Drug: ianalumab
Normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.
Study: NCT05770219
Drug: TAK-755
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
Study: NCT05172934
Drug: intra-arterial tenecteplase
Normalized name: methotrexate
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intra-arterial drug administered after mechanical thrombectomy
Study: NCT06117891
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
Study: NCT06117891
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
Study: NCT06117891
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Study: NCT06117891
Drug: Tremelimumab,
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Study: NCT05276973
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05276973
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05276973
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05161572
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1.
Study: NCT05161572
Drug: Tegafur-Gimeracil-Oteracil
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. S-1 is administered orally at 40-60 mg twice a day for 14 consecutive days. Then, the patients will have a one-week rest period. The dose of S-1 is according to the body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily.
Study: NCT04566991
Drug: Deferoxamine
Normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine.
Study: NCT05969795
Drug: Progesterone 100 Mg Vaginal Insert
Normalized name: progesterone 100 MG Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy
Study: NCT04395508
Drug: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PH FDC SC is given as a fixed dose (i.e. non-weight based) subcutaneous injection. Two dosage configurations of PH FDC SC may be administered in the study: a 15-millilitre (mL) loading dose consisting of 1200 milligrams (mg) pertuzumab and 600 mg trastuzumab and a 10-mL maintenance dose consisting of 600 mg pertuzumab and 600 mg trastuzumab. Participants who have had ≥6 weeks since their last P+H IV, PH FDC SC, or are receiving trastuzumab SC treatment must receive a loading dose before continuing with maintenance doses for subsequent administrations. Note that participants receiving trastuzumab SC only (i.e. without pertuzumab) must receive a loading dose regardless of time since last treatment.
Study: NCT06347159
Drug: EDG-7500
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid suspension formulation of EDG-7500
Study: NCT06347159
Drug: EDG-7500
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid oral formulation of EDG-7500
Study: NCT06220643
Drug: triamcinolone acetonide plus lidocaine
Normalized name: Triamcinolone Acetonide
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%)
Study: NCT05161572
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The immunotherapy includes perioperative treatment and postoperative maintenance treatment. The PD-1 mAb used will be sintilimab, and the dose is 200 mg intravenously every three weeks. Regardless of which arm, the courses of immunotherapy that will be received by the enrolled patients are the same: 3 times preoperatively, 3 times postoperatively, and then maintained until one year after surgery.
Study: NCT04266275
Drug: Curcumin C3 Complex
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.
Study: NCT06160791
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered Orally (PO)
Study: NCT06160791
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT06160791
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered PO or IV
Study: NCT06211088
Drug: famotidine plus10ml normal saline
Normalized name: NS-2
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine
Study: NCT05382442
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
Study: NCT05382442
Drug: AK117
Normalized name: Immunoglobulin g4 (225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal ak117 .gamma.4-chain), disulfide with human-mus musculus monoclonal ak117 .kappa.-chain, dimer
DrugBank: Ligufalimab (DB17542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
Study: NCT05382442
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin via IV infusion
Study: NCT05382442
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan via IV infusion
Study: NCT05382442
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil via IV infusion
Study: NCT06401603
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV